Skip to main content
SpringerLink
Log in
Book cover

Addiction Medicine pp 129–157Cite as

Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence

  • Chapter
  • First Online:

Abstract

The current review illustrates the extent to which human laboratory methods of abuse liability assessment have been useful in the development of medications for alcohol and drug dependence. The three medications for the treatment of alcohol dependence (disulfiram, naltrexone, and acamprosate) were approved by the Food and Drug Administration without such studies, but increasingly, human laboratory studies are improving our understanding of the mechanism and selectivity of their effects. In contrast, many putative treatments for cocaine dependence, and to a lesser extent methamphetamine dependence, have been screened by human laboratory studies—though no effective treatments have yet been developed. Conclusions suggest that methods to screen the safety and possible efficacy of putative treatments in the human laboratory are validated, but that the efficacy of outpatient treatment also involves compliance factors which have not been adequately modeled in human laboratory studies.

This is a preview of subscription content, log in via an institution.

Chapter
USD   29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD   299.00
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD   379.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info
Hardcover Book
USD   329.99
Price excludes VAT (USA)
  • Durable hardcover edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Learn about institutional subscriptions

References

  1. Ait-Daoud N, Roache JD, Dawes MA, Liu L, Wang X-Q, Javors MA, Seneviratne C, Johnson BA (2009) Can serotonin transporter genotype predict craving in alcoholism? Alcohol Clin Exp Res 33:1329–1335

    Article  PubMed  CAS  Google Scholar 

  2. Altman JL, Meyer RE, Mirin SM, McNamee, McDougle HB (1976) Opiate antagonists and the modification of heroin self-administration behavior in man: an experimental study. Int J Addict 11:485–499

    PubMed  CAS  Google Scholar 

  3. Ambre JJ, Berlknap SM, Nelson J, Ruo TI, Shin SG, Atkinson AJ (1988) Acute tolerance to cocaine in humans. Clin Pharmacol Therap 44:1–8

    Article  CAS  Google Scholar 

  4. Anonymous (2005) Alcohol and drugs: mixing can be risky. Consumer Rep 70:49

    Google Scholar 

  5. Anonymous (2000) National highway traffic safety administration (NHTSA) notes. Commentary: drugged driving—different spin on an old problem [comment]. Ann Emergency Med 35:399–400

    Google Scholar 

  6. Anton RF, O’Malley SS, Ciraulo DA, et al (for the COMBINE Group) (2006) Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. J Am Med Assoc 295:2003–2017

    Article  CAS  Google Scholar 

  7. APA (2000) Diagnostic and statistical manual of mental disorders fourth edition text revision (DSM-IV-TR). American Psychiatric Association, Washington, DC

    Google Scholar 

  8. Avants SK, Margolin A, Kosten TR, Cooney NL (1995) Differences between responders and nonresponders to cocaine cues in the laboratory. Addict Behav 20:215–224

    Article  PubMed  CAS  Google Scholar 

  9. Baker JR, Jatlow P, McCance-Katz EF (2007) Disulfiram effects on responses to intravenous cocaine administration. Drug Alcohol Depend 87:202–209

    Article  PubMed  CAS  Google Scholar 

  10. Balster RL, Bigelow GE (2003) Guideline and methodological reviews concerning drug abuse liability assessment. Drug Alcohol Depend 70:S13–S40

    Article  PubMed  Google Scholar 

  11. Barcelona Conference (1991) Barcelona meeting on clinical testing of drug abuse liability: consensus statement and recommendations. Br J Addict 86:1527–1528

    Article  Google Scholar 

  12. Beecher HK (1959) Measurement of subjective responses: quantitative effects of drugs. Oxford University, New York

    Google Scholar 

  13. Berger SP, Hall S, Mickalian JD, Reid MS, Crawford Cl, Delucchi K et al (1996) Haloperidol antagonism of cue-elicited cocaine craving. The Lancet 347:504–508

    Article  CAS  Google Scholar 

  14. Bickel WK, DeGrandpre RJ, Higgins ST (1993) Behavioral economics: a novel experimental approach to the study of drug dependence. Drug Alcohol Depend 33:173–192

    Article  PubMed  CAS  Google Scholar 

  15. Bickel WK, DeGrandpre RJ, Higgins ST (1995) The behavioral economics of concurrent drug reinforcers: a review and reanalysis of drug self-administration research. Psychopharmacology 118:250–259

    Article  PubMed  CAS  Google Scholar 

  16. Bigelow GE (1991) Human drug abuse liability assessment: opioids and analgesics. Br J Addict 86:1625–1628

    Article  Google Scholar 

  17. Bohn MJ, Krahn DD, Staehler BA (1995) Development and initial validation of a measure of drinking urges in abstinent alcoholics. Alcohol Clin Exp Res 19:600–606

    Article  PubMed  CAS  Google Scholar 

  18. Brasser SM, McCaul ME, Houtsmuller EJ (2004) Alcohol effects during acamprosate treatment: a dose-response study in humans. Alcohol Clin Exp Res 28:1074–1083

    Article  PubMed  CAS  Google Scholar 

  19. Brauer LK, de Wit H (1997) High dose pimozide does not block amphetamine-induced euphoria in normal volunteers. Pharmacol Biochem Behav 56:265–272

    Article  PubMed  CAS  Google Scholar 

  20. Brewer C (1984) How effective is the standard dose of disulfiram: a review of the alcohol-disulfiram reactions in practice. Brit J Psychiat 144:200–202

    Article  PubMed  CAS  Google Scholar 

  21. Brown SA, Goldman MS, Christiansen BA (1985) Do alcohol expectancies mediate drinking patterns of adults? J Consulting Clin Psychol 53:512–519

    Article  CAS  Google Scholar 

  22. Buchhalter AR, Fant RV, Henningfield JE (2008) Novel pharmacological approaches for treating tobacco dependence and withdrawal: current status. Drugs 68:1067–1088

    Article  PubMed  CAS  Google Scholar 

  23. Carroll KM, Fenton LR, Ball SA, Nich C, Frankforter TL, Shi J, Rounsaville BJ (2004) Efficacy of disulfiram and cognitive behavior therapy in cocaine-dependent outpatients. Arch Gen Psychiatr 61:264–272

    Article  PubMed  CAS  Google Scholar 

  24. Carter BL, Tiffany ST (1999) A Meta-Analysis: meta-analysis of cue-reactivity in addiction research. Addiction 94:327–340

    Article  PubMed  CAS  Google Scholar 

  25. Chutuape MAD, de Wit H (1994) Relationship between subjective effects and drug preferences: ethanol and diazepam. Drug Alcohol Depend 34:243–251

    Article  PubMed  CAS  Google Scholar 

  26. Christensen JK, Moller IW, Ronsted P, Angelo HR, Johansson ZB (1991) Dose-effect relationship of disulfiram in human volunteers. I: clinical studies. Pharmacol Toxicol 68:163–165

    Article  PubMed  CAS  Google Scholar 

  27. Collins ED, Vosburg SK, Hart CL, Haney M, Foltin RW (2003) Amantidine does not modulate reinforcing, subjective or cardiovascular effects of cocaine in humans. Pharmacol Biochem Behav 76:401–407

    Article  PubMed  CAS  Google Scholar 

  28. Comer SD, Ashworth JB, Foltin RW, Johanson ED, Zacny JP, Walsh SL (2008) The role of human drug self-administration procedures in the development of medications. Drug Alcohol Depend 96:1–15

    Article  PubMed  CAS  Google Scholar 

  29. Comer SD, Collins ED, Kleber HD, Nuwayser ES, Kerrigan JH, Fischman MW (2002) Depot naltrexone: Long-lasting antagonism of the effects of heroin in humans. Psychopharmacology 159: 351–360

    Article  PubMed  CAS  Google Scholar 

  30. Comer SD, Collins, ED, Wilson ST, Donovan MR, Foltin RW, Fischman MW (1998) Effects of an alternative reinforcer on intravenous heroin self-administration by humans. Eur J Pharmacol 345:13–26

    Article  PubMed  CAS  Google Scholar 

  31. Conners GJ, O’Farrell TJ, Cutter HSG, Thompson DL (1986) Alcohol expectancies among male alcoholics, problems drinkers, and nonproblem drinkers. Alcohol Clin Exp Res 10:667–671

    Article  Google Scholar 

  32. Dackis CA, Lynch KG, Yu E, Samaha FF, Kampman KM, Cornish JW, Rowan A, Poole S, White L, O’Brien CP (2003) Modafinil and cocaine: a double-blind, placebo-controlled drug interaction study. Drug Alcohol Depend 20:29–37

    Article  CAS  Google Scholar 

  33. Davidson D, Palfai T, Bird C, Swift R (1999) Effects of naltrexone on alcohol self-administration in heavy drinkers. Alcohol Clin Exp Res 23:195–203

    Article  PubMed  CAS  Google Scholar 

  34. Deptula D, Pomara N (1990) Effects of antidepressants on human performance: a review. J Clin Psychopharmacol 10:105–111

    Article  PubMed  CAS  Google Scholar 

  35. de Wit H, Uhlenhuth EH, Johanson CE (1986) Individual differences in the reinforcing and subjective effects of amphetamine and diazepam. Drug Alcohol Depend 16:341–360

    Article  PubMed  Google Scholar 

  36. de Witte P, Littleton J, Parot P, Koob G (2005) Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action CNS Drugs 19:517–537

    Google Scholar 

  37. Donny EC, Bigelow GE, Walsh SL (2003) Choosing to take cocaine in the human laboratory: effects of cocaine dose, inter-choice interval, and magnitude of alternative reinforcement. Drug Alcohol Depend 69:289–301

    Article  PubMed  CAS  Google Scholar 

  38. Donny EC, Braser SM, Bigelow GE, Stitzer ML, Walsh SL (2005) Methadone doses of 100 mg or greater are more effective than lower doses at suppressing heroin self-administration in opioid-dependent volunteers. Addiction 100:1496–1509

    Article  PubMed  Google Scholar 

  39. Doty P, de Wit H (1995) Effects of naltrexone pretreatment on the subjective and performance effects of ethanol in social drinkers Behav Pharmacol 6:386–394

    Article  PubMed  CAS  Google Scholar 

  40. Drobes DJ, Anton R, Thomas SE, Voronin K (2003) A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene. Neuropsychopharmacology 28:755–764

    Article  PubMed  CAS  Google Scholar 

  41. Drummond DC (2000) Human models in craving research: what does cue-reactivity have to offer clinical research? Addiction 95(Suppl):S129–S144

    PubMed  Google Scholar 

  42. Dudish-Poulsen SA, Hatsukami DK (1997) Dissociation between subjective and behavioral responses after cocaine stimuli presentations. Drug Alcohol Depend 47:1–9

    Article  PubMed  Google Scholar 

  43. Dykstra LA, Preston KL, Bigelow GE (1997) Discriminative stimulus and subjective effects of opioids with mu and kappa activity: data from laboratory animals and human subjects. Psychopharmacology 130:14–27

    Article  PubMed  CAS  Google Scholar 

  44. Anderson AL, Reid MS, Li SH, Holmes T, Shemanski L, Slee A, Smith EV, Kahn R, Chiang N, Vocci F, Ciraulo D, Dackis C, Roache JD, Salloum IM, Somoza E, Urschel HC 3rd, Elkashef AM (2009) Modafinil for the treatment of cocaine dependence. Drug and Alcohol Dependence 104:133–139

    Article  PubMed  CAS  Google Scholar 

  45. Elkashef A, Holmes TH, Bloch DA, Shoptaw S, Kampman K, Reid MS, Somoza E, Ciraulo D, Rostrosen J, Leiderman D, Montgomery A, Vocci F (2005) Retrospective analyses of pooled data from CREST I and CREST II trials for treatment of cocaine dependence. Addiction 100:91–101

    Article  PubMed  Google Scholar 

  46. Elkashef AM, Rawson RA, Anderson AL, Li SH, Holmes T, Smith EV, Chiang N, Kahn R, Vocci F, Ling W, Pearce VJ, McCann M, Campbell J, Gorodetzky C, Haning W, Carlton B, Mawhinney J, Weis D (2008) Bupropion for the treatment of methamphetamine dependence. Neuropsychopharmacology 33:1162–1170

    Article  PubMed  CAS  Google Scholar 

  47. Evans SM, Walsh SL, Levin FR, Foltin RW, Fischman MW, Bigelow GE (2001) The effects of flupenthixol on the subjective and cardiovascular effects of intravenous cocaine in humans. Drug Alcohol Depend 64:271–283

    Article  PubMed  CAS  Google Scholar 

  48. Fischman MW (1989) Relationship between self-reported drug effects and their reinforcing effects: studies with stimulant drugs. In: Fischman MW, Mellow NK (eds) Testing for abuse liability of drugs in humans. National Institute on Drug Abuse Research Monograph No. 92, DHEW Pub. No. (ADM) 89–163, U.S. Government Printing Office, Washington, DC

    Google Scholar 

  49. Fischman MW, Foltin RW (1991) Utility of subjective-effects in measurements assessing abuse liability of drugs in humans. Br J Addict 86:1563–1570

    Article  PubMed  CAS  Google Scholar 

  50. Fischman MW, Foltin RW, Nestadt G, Pearlson GD (1990) Effects of desipramine maintenance on cocaine self-administration by humans. J Pharmacol Exp Ther 253:760–770

    PubMed  CAS  Google Scholar 

  51. Fischman MW, Johanson CE (1998) Ethical and practical issues involved in behavioral pharmacology research that administers drugs of abuse to human volunteers. Behav Pharmacol 9:479–498

    Article  PubMed  CAS  Google Scholar 

  52. Foltin RW, Fischman MW (1991) Assessment of abuse liability of stimulant drugs in humans: a methodological survey. Drug Alcohol Depend 28:3–48

    Article  PubMed  CAS  Google Scholar 

  53. Foltin RW, Fischman MW (1991) Methods for the assessment of abuse liability of psychomotor stimulants and anorectic agents in humans. Br J Addict 86:1633–1640

    Article  PubMed  CAS  Google Scholar 

  54. Foltin RW, Fischman MW (1991) Smoked and intravenous cocaine in humans: acute tolerance, cardiovascular and subject effects. J Pharmacol Exp Ther 257:247–261

    PubMed  CAS  Google Scholar 

  55. Foltin RW, Fischman MW (1994) Effects of buprenorphine on the self-administration of cocaine by humans. Behav Pharmacol 5:79–89

    Article  PubMed  CAS  Google Scholar 

  56. Foltin RW, Fischman MW (1996) Effects of methadone or buprenorphine maintenance on the subjective and reinforcing effects of intravenous cocaine in humans. J Pharmacol Exp Ther 278:1153–1164

    PubMed  CAS  Google Scholar 

  57. Foltin RW, Fischman MW, Levin FR (1995) Cardiovascular effects of cocaine in humans: laboratory studies. Drug Alcohol Depend 37:193–210

    Article  PubMed  CAS  Google Scholar 

  58. Foltin RW, Ward AS, Haney M, Hart CL, Collins ED (2003) The effects of escalating doses of smoked cocaine in humans. Drug Alcohol Depend 70:149–157

    Article  PubMed  CAS  Google Scholar 

  59. Fraser HF, Jasinski DR (1977) The assessment of the abuse potentiality of sedative/hypnotics (depressants): methods used in man. In: Martin WR (ed) Drug addiction I: morphine, sedative-hypnotic and alcohol dependence. Handbook of experimental pharmacology, vol 45. Springer, Heidelberg, pp 159–196

    Google Scholar 

  60. Fraser HF, Van Horn GC, Isbell H (1956) Studies on N-Allylnormorphine in man: antagonism to morphine and heroin and effects of mixtures of N-Allylnormorphine and morphine. Am J Med Sci 231:1–8

    Article  PubMed  CAS  Google Scholar 

  61. Fraser HF, Van Horn GC, Martin WR, Wolbach AB, Isbell H (1961) Methods for evaluating addiction liability. (A) “Attitude” of opiate addicts toward opiate-like drugs. (B) A short-term “direct” addiction test. J Pharmacol Exp Ther 133:371–387

    PubMed  CAS  Google Scholar 

  62. Gorelick DA, Gardner EL, Xi ZX (2004) Agents in development for the management of cocaine abuse. Drug 64:1547–1573

    Article  CAS  Google Scholar 

  63. Gottschalk PCH, Kosten TR (2002) Isradipine enhancement of cerebral blood flow in abstinent cocaine abusers with and without chronic perfusion deficits. Am J Addict 11:200–208

    Article  PubMed  CAS  Google Scholar 

  64. Grabowski J, Rhoades H, Schmitz J, Stotts A, Daruzska LA, Creson D, Moeller FG (2001) Dextroamphetamine for cocaine-dependence treatment: a double-blind randomized clinical trial. J Clin Psychopharmacol 21:522–526

    Article  PubMed  CAS  Google Scholar 

  65. Grabowski J, Rhoades H, Stotts A, Cowan K, Kopecky C, Dougherty A, Moeller FG, Hassan S, Schmitz J (2004) Agonist-like or antagonist-like treatment of cocaine dependence with methadone for heroin dependence: two double-blind randomized clinical trials. Neuropsychopharmacology 29:969–981

    Article  PubMed  CAS  Google Scholar 

  66. Grabowski J, Roache JD, Schmitz JM, Rhoades H, Creson D, Korszun A (1997) Replacement medication for cocaine dependence: methylphenidate. J Clin Psychopharmacol 17:485–488

    Article  PubMed  CAS  Google Scholar 

  67. Grabowski J, Shearer J, Merrill J, Negus SS (2004) Agonist-like, replacement pharmacotherapy for stimulant abuse and dependence. Addictive Behaviors 29:1439–1464

    Article  PubMed  Google Scholar 

  68. Grady TA, Broocks A, Canter SK, Pigott TA, Dubbert B, Hill JL, Murphy DL (1996) Biological and behavioral response to d-amphetamine, alone and in combination with the serotonin3 receptor antagonist ondansetron, in healthy volunteers. Psychiat Res 64:1–10

    Article  CAS  Google Scholar 

  69. Griffiths RR, Bigelow GE, Ator NA (2003) Principles of initial experimental drug abuse liability assessment in humans. Drug Alcohol Depend 70:S41–S54

    Article  PubMed  Google Scholar 

  70. Griffiths RR, Bigelow GE, Henningfield JE (1980) Similarities in animal and human drug-taking behavior. In: Mello NK (ed) Advances in substance abuse, vol 1. JAI, Greenwich, CT, pp 1–90

    Google Scholar 

  71. Griffiths RR, Woodson PP (1988) Reinforcing effects of caffeine in humans. J Pharmacol Exp Ther 246:21–9

    PubMed  CAS  Google Scholar 

  72. Griffiths RR, Troisi JR, Silverman K, Mumford GK (1993) Multiple-choice procedure: an efficient approach for investigating drug reinforcement in humans. Behav Pharmacol 4:3–13

    Article  PubMed  CAS  Google Scholar 

  73. Griffiths RR, Rush CR, Puhala KA (1996) Validation of the multiple-choice procedure for investigating drug reinforcement in humans. Exp Clin Psychopharmacol 4:97–106

    Article  Google Scholar 

  74. Guardia J, Segura L, Gonzalvo B, Iglesias L, Roncero C, Cardus M et al (2004). A double-blind, placebo-controlled study of olanzapine in the treatment of alcohol-dependence disorder. Alcohol Clin Exp Res 28:736–745

    Article  PubMed  CAS  Google Scholar 

  75. Haberny KA, Walsh SL, Ginn DH, Wilkins JN, Garner JE, Setoda D, Bigelow GE (1995) Absence of acute cocaine interactions with the MAO-B inhibitor selegiline. Drug Alcohol Depend 39:55–62

    Article  PubMed  CAS  Google Scholar 

  76. Haertzen CA (1966) Development of scales based on patterns of drug effects, using the Addiction Research Center Inventory (ARCI). Psychol Rep 18:163–194

    Article  PubMed  CAS  Google Scholar 

  77. Hald J, Jacobsen, E, Larsen V (1948) The sensitizing effect of tetraethylthiuramdisulphide (Antabus) to ethylalcohol. Acta Pharmacol 4:285–296

    Article  CAS  Google Scholar 

  78. Halikas JS, Kuhn KL, Crosby R, Carlson G, Crea F (1991) The measurement of craving in cocaine patients using the Minnesota cocaine craving scale. Comprehensive Psychiatry 32:22–27

    Article  PubMed  CAS  Google Scholar 

  79. Hameedi FA, Rosen MI, McCance-Katz EF, McMahon TJ, Price LH, Jatlow PI, Woods SW, Kosten TR (1995) Behavioral, physiological, and pharmacological interaction of cocaine and disulfiram in humans. Biol Psychiatry 37:560–563

    Article  PubMed  CAS  Google Scholar 

  80. Haney M, Collins ED, Ward AS, Foltin FW, Fischman MW (1999) Effect of a selective dopamine D1 agonist (ABT-431) on smoked cocaine self-administration in humans. Psychopharmacology 143:102–110

    Article  PubMed  CAS  Google Scholar 

  81. Haney M, Foltin RW, Fischman MW (1998) Effects of pergolide on intravenous cocaine self-administration in men and women. Psychopharmacology 137:15–24

    Article  PubMed  CAS  Google Scholar 

  82. Haney M, Hart CL, Reed SC, Vosburg SK, Foltin RW (2007). Aripiprazole increases cocaine self-administration in humans. Presented at International Study Group Investigating Drugs as Reinforcers (ISGIDAR), Quebec City, Canada

    Google Scholar 

  83. Haney M, Spealman R (2008) Controversies in translational research: drug self-administration. Psychopharmacology 199:403–419

    Article  PubMed  CAS  Google Scholar 

  84. Haney M, Ward AS, Foltin RW, Fischman MW (2001) Effects of ecopipam, a selective D1 antagonist, on smoked cocaine self-administration by humans. Psychopharmacology 155:330–337

    Article  PubMed  CAS  Google Scholar 

  85. Harris DS, Batki SL, Berger SP (2004) Fluoxetine attenuates adrenocortical but not subject response to cocaine cues. Am J Drug Alcohol Abuse 30:765–782

    Article  PubMed  Google Scholar 

  86. Hart CL, Haney M, Foltin RW, Fischman MW (2002) Effects of the NMDA antagonist memantine on human methamphetamine discrimination. Psychopharmacology 164:376–384

    Article  PubMed  CAS  Google Scholar 

  87. Hart CL, Ward AS, Collins ED, Haney M, Foltin RW (2004) Gabapentin maintenance decreases smoked cocaine-related subjective effects, but not self-administration by humans. Drug Alcohol Depend 73:279–287

    Article  PubMed  CAS  Google Scholar 

  88. Hartz DT, Frederick-Osborne SL, Galloway GP (2001) Craving predicts use during treatment for methamphetamine dependence: a prospective, repeated-measures, within-subject analysis. Drug Alcohol Depend 63:269–276

    Article  PubMed  CAS  Google Scholar 

  89. Heishman SJ, Singleton EG (2006) Assessment of cannabis craving using the marijuana craving questionnaire. 123:209–216

    Google Scholar 

  90. Helmus TC, Tancer M, Johanson CE (2005) Reinforcing effects of diazepam under anxiogenic conditions in individuals with social anxiety. Exp Clin Psychopharmacol 13:348–56

    Article  PubMed  Google Scholar 

  91. Henningfield JE, Cohen C, Heishman SJ (1991) Drug self-administration methods in abuse liability evaluation. Br J Addict 86:1571–1577

    Article  PubMed  CAS  Google Scholar 

  92. Henningfield JE, Lukas SE, Bigelow GE (1986) Human Studies of Drugs as Reinforcers. In: Goldberg SR, Stolerman IP (eds) Behavioral analysis of drug dependence. Academic, Orlando, FL, p 69

    Google Scholar 

  93. Hernandez-Avila CA, Oncken C, Van Kirk J, Wand G, Kranzler HR (2002) Adrenocorticotropin and cortisol responses to a naloxone challenge and risk of alcoholism. Biol Psychiatr 51:652–658

    Article  CAS  Google Scholar 

  94. Higgins ST, Bickel WK, Hughes JR (1994) Influence of an alternative reinforcer on human cocaine self-administration. Life Sci 55:179–187

    Article  PubMed  CAS  Google Scholar 

  95. Hill HF, Chapman R, Kornell JA, Sullivan KM, Saeger LC, Benedetti C (1990) Self-administration of morphine in bone marrow transplant patient reduces drug requirement. Pain 40:121–129

    Article  PubMed  CAS  Google Scholar 

  96. Hindmarch I, Kerr JS, Sherwood N (1991) The effects of alcohol and others drugs on psychomotor performance and cognitive function. Alcohol Alcohol 26:17–79

    Google Scholar 

  97. Houtsmuller EJ, Notes LD, Newton T, van Sluis N, Chiang N, Elkashef A, Bigelow GE (2004) Transdermal selegiline and intravenous cocaine: safety and interactions. Psychopharmacology 172:31–40

    Article  PubMed  CAS  Google Scholar 

  98. Huestis MA, Boyd SJ, Heishman SJ, Preston KL, Bonnet D, Le Fur G, Gorelick DA (2007) Single and multiple doses of rimonabant antagonize acute effects of smoked cannabis in male cannabis users. Psychopharmacology 194:505–515

    Article  PubMed  CAS  Google Scholar 

  99. Hutchison KE, McGeary J, Smolen A, Bryan AD, Swift RM (2002). The DRD4 VNTR polymorphism moderates craving after alcohol consumption. Health Psychol 21: 139–146

    Article  PubMed  Google Scholar 

  100. Hutchison KE, McGeary J, Smolen A, Wooden A (2001). Craving after alcohol consumption: olanzapine and the DRD4 VNTR polymorphism. Alcohol Clin Exp Res 25:66a

    Google Scholar 

  101. Hutchison KE, Ray L, Sandman E, Rutter M-C, Peters A, Davidson D, Swift R (2006) The effect of olanzapine on craving and alcohol consumption Neuropsychopharmacology 31:1310–1317

    PubMed  CAS  Google Scholar 

  102. Hutchison KE, Wooden A, Swift RM, Smolen A, McGeary J, Adler L et al (2003) Olanzapine reduces craving for alcohol: a DRD4 VNTR polymorphism by pharmacotherapy interaction. Neuropsychopharmacology 28:1882–1888

    Article  PubMed  CAS  Google Scholar 

  103. Jaffe JH, Cascella NG, Kumor KM, Sherer MA (1989) Cocaine-induced cocaine craving. Psychopharmacology 97:59–64

    Article  PubMed  CAS  Google Scholar 

  104. Jasinski DR (1977) Assessment of the abuse potentiality of morphine like drugs (methods used in man. In: Martin WR (ed) Handbook of experimental pharmacology, vol 45. Springer, New York, pp 197–258

    Google Scholar 

  105. Jasinski DR, Martin WR, Haertzen CA (1967) The human pharmacology and abuse potential of N-Allylnormxoymorphone (Naloxone). J Pharmacol Exp Ther 157:420–426

    PubMed  CAS  Google Scholar 

  106. Jasinski DR, Pevnick JS, Griffith JD (1978) Human pharmacology and abuse potential of the analgesic buprenorphine: a Potential agent for treating narcotic addiction. Arch Gen Psychiatry 35:501–516

    Article  PubMed  CAS  Google Scholar 

  107. Johanson C (1991) Discriminative stimulus effects of psychomotor stimulants and benzodiazepines in humans. In: Glennon R, Jarbe T, Frankenheim J (eds) Drug discrimination: applications to drug abuse research, vol 116. National Institute on Drug Abuse, Rockville, MD, pp 181–196

    Google Scholar 

  108. Johanson CE, Lundahl LH, Lockhart N, Schubiner H (2006) Intravenous cocaine discrimination in humans. Exp Clin Psychopharmacol 14:99–108

    Article  PubMed  CAS  Google Scholar 

  109. Johanson CE, Uhlenhuth EH (1980a) Drug preference and mood in humans: diazepam. Psychopharmacology 71:269–273

    Article  PubMed  CAS  Google Scholar 

  110. Johanson CE, Uhlenhuth EH (1980b) Drug preference and mood in humans: D-Amphetamine. Psychopharmacology 71:275–279

    Article  PubMed  CAS  Google Scholar 

  111. Johansson B, Angelo HR, Christensen JK, Moller IW, Ronsted P (1991) Dose-effect relationship of disulfiram in human volunteers. II: a study of the relation between the disulfiram-alcohol reaction and plasma concentrations of acetaldehyde, diethyldithiocarbamic acid methyl ester, and erythrocyte aldehyde dehydrogenase activity. Pharmacology and Toxicology 68:166–170

    Article  PubMed  CAS  Google Scholar 

  112. Johnson BA (2000) Serotonergic agents and alcoholism treatment: rebirth of the subtype concept—an hypothesis. Alcohol Clin Exp Res 24:1597–1601

    PubMed  CAS  Google Scholar 

  113. Johnson BA (2008) Update on neuropharmacological treatments for alcoholism: scientific basis and clinical findings. Biochem Pharmacol 75:34–56

    Article  PubMed  CAS  Google Scholar 

  114. Johnson BA, Ait-Daoud N, Bowden CL, DiClemente CC, Roache JD, Lawson K, Javors MA, Ma JZ (2003) Oral topiramate for treatment of alcohol dependence: a randomized controlled trial. Lancet 361:1677–1685

    Article  PubMed  CAS  Google Scholar 

  115. Johnson BA, Ait-Daoud N, Elkashef AM, Smith EV, Kahn R, Vocci F, Li SH, Bloch DA, Methamphetamine Study Group (2008) A preliminary randomized, double-blind, placebo-controlled study of the safety and efficacy of ondansetron in the treatment of methamphetamine dependence. Int J Neuropsychopharmacol 11:1–14

    Article  PubMed  CAS  Google Scholar 

  116. Johnson B, Barron B, Fang B, Lamki L, Wagner L, Wells L, Kenny P, Overton D, Dhother S, Abramson D, Chen R, Kramer L (1998) Isradipine prevents global and regional cocaine-induced changes in brain blood flow: a preliminary study. Psychopharmacology 136:335–341

    Article  PubMed  CAS  Google Scholar 

  117. Johnson BA, Campling GM, Griffiths P, Cowen PJ (1993) Attenuation of some alcohol-induced mood changes and the desire to drink by 5-HT3 receptor blockade: a preliminary study in healthy male volunteers. Psychopharmacology 112:142–144

    Article  PubMed  CAS  Google Scholar 

  118. Johnson BA, Devous MD, Ruiz P, Ait-Daoud N (2001) Treatment advances for cocaine-induced ischemic stroke: focus on dihydropyridine-class calcium channel antagonists. Am J Psychiatry 158:1191–1198

    Article  PubMed  CAS  Google Scholar 

  119. Johnson BA, O’Malley SS, Ciraulo DA, Roache JD, Chambers RA, Sarid-Segal O, Couper D (2003) Dose-ranging kinetics and behavioral pharmacology of naltrexone and acamprosate, both alone and combined, in alcohol-dependent subjects. J Clin Psychopharmacol 23(3):279–291

    Google Scholar 

  120. Johnson BA, Roache JD, Ait-Daoud N, Wallace C, Wells L, Dawes M, Wang Y (2005) Effects of isradipine, a dihydropyridine-class calcium-channel antagonist, on d-methamphetamine’s subjective and reinforcing effects. Int J Neuropsychopharmacol 8:203–213

    Article  PubMed  CAS  Google Scholar 

  121. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Mauldin JB (2004) Effects of isradipine on cocaine-induced subjective mood. J Clin Psychopharmacol 24:180–191

    Article  PubMed  CAS  Google Scholar 

  122. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ (2007) Effects of acute topiramate dosing on methamphetamine-induced subjective mood. Int J Neuropsychopharmacol 10:85–98

    Article  PubMed  CAS  Google Scholar 

  123. Johnson BA, Roache JD, Ait-Daoud N, Wells LT, Wallace CL, Dawes MA, Liu L, Wang XQ (2007) Effects of topiramate on methamphetamine-induced changes in attentional and perceptual-motor skills of cognition in recently abstinent methamphetamine-dependent individuals. Prog NeuroPsychopharm Biol Psychiat 31:123–130

    Article  CAS  Google Scholar 

  124. Johnson BA, Roache JD, Bordnick PS, Ait-Daoud N (1999) Isradipine, a dihydropryidine-class calcium channel antagonist, attenuates some of d-methamphetamine’s positive subjective effects: a preliminary study. Psychopharmacology 144:295–300

    Article  PubMed  CAS  Google Scholar 

  125. Johnson BA, Roache JD, Javors MA, DiClemente CC, Cloninger CR, Prihoda TJ, Bordnick PS, Ait-Daoud N, Hensler J (2000) Ondansetron for reduction of drinking among biologically predisposed alcoholic patients. J Am Med Assoc 284:963–971

    Article  CAS  Google Scholar 

  126. Johnson BA, Rosenthal N, Capece JA et al (2007) Topiramate for treating alcohol dependence: a randomized controlled trial. JAMA 298:1641–1651

    Article  PubMed  CAS  Google Scholar 

  127. Johnson BA, Wells LT, Roache JD, Wallace C, Ait-Daoud N, Wang Y (2005) Isradipine decreases the hemodynamic response of cocaine and methamphetamine: results from two human laboratory studies. Am J Hypertension 18:813–822

    Article  CAS  Google Scholar 

  128. Jones BE, Prada JA (1975) Drug-seeking behavior during methadone maintenance. Psychopharmacology 41:7–10

    Article  CAS  Google Scholar 

  129. Jonsson LE (1972) Pharmacological blockade of amphetamine effects in amphetamine dependent subjects. Eur J Clin Pharmacol 4:206–211

    Article  Google Scholar 

  130. Kampman KM, Pettinati H, Lynch KG, Sparkman T, O’Brien CP (2003) A pilot trial of olanzapine for the treatment of cocaine dependence. Drug Alcohol Depend 70:265–273

    Article  PubMed  CAS  Google Scholar 

  131. Keltner N, Vance D (2008) Incarcerated care and quetiapine abuse. Perspectives Psychiatric Care 44:202–206

    Article  Google Scholar 

  132. Kenna GA, Nielsen DM, Mello P, Schiesl A, Swift RA (2007) Pharmacotherapy of dual substance abuse and dependence. CNS Drugs 21:213–237

    Article  PubMed  CAS  Google Scholar 

  133. King AC, Volpicelli JR, Frazer A, O’Brien CP (1997) Effect of naltrexone on subjective alcohol response in subjects at high and low risk for future alcohol dependence. Psychopharmacology 129:15–22

    Article  PubMed  CAS  Google Scholar 

  134. Kirchmayer U, Davoli M, Verster Ad, Amato, L, Ferri A, Perucci CA (2002) A systematic review on the efficacy of naltrexone maintenance treatment in opioid dependence. Addiction 97:1241–1249

    Article  PubMed  Google Scholar 

  135. Kosten T, Gawin FH, Silverman DG, Fleming J, Compton M, Jatlow P, Byck R (1992) Intravenous cocaine challenges during desipramine maintenance. Neuropsychopharmacology 7:169–176

    PubMed  CAS  Google Scholar 

  136. Kosten TR, Woods SW, Rosen MI, Pearsall HR (1999) Interactions of cocaine with nimodipine: a brief report. Am J Addict 8:77–81

    Article  PubMed  CAS  Google Scholar 

  137. Kozlowski LT, Mann RE, Wilkinson, Poulos CX (1989) “Cravings” are ambigiuous: ask about urges or desires. Addict Behav 14:443–445

    Article  PubMed  CAS  Google Scholar 

  138. Kranzler HR, Gage A (2008) Acamprosate efficacy in alcohol-dependent patients: summary of results from three pivotal trials. Am J Addict 17:70–76

    Article  PubMed  Google Scholar 

  139. Krishnan-Sarin S, Krystal JH, Shi J, Pittman B, O'Malley SS (2007) Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. Biol Psychiat 62(6):694–697

    Article  PubMed  CAS  Google Scholar 

  140. Kristenson H (1995) How to get the best out of antabuse. Alcohol Alcoholism 30:775–783

    CAS  Google Scholar 

  141. Lamb RJ, Preston KL, Schindler CW, Meisch RA, Davis F, Katz JL, Henningfield JE, Goldberg SR (1991) The reinforcing and subjective effects of morphine in post-addicts: a dose-response study. J Pharmacol Exp Ther 259:1165–1173

    PubMed  CAS  Google Scholar 

  142. Leyton M, Casey KF, Delaney JS, Kolivakis T, Benkelfat C (2005) Cocaine craving, euphoria, and self-administration: a preliminary study of the effect of catecholamine precursor depletion. Behav Neurosci 119:1619–1627

    Article  PubMed  CAS  Google Scholar 

  143. Lile JA, Stoops WW, Glaser PEA, Hays LR, Rush CR (2004) Acute administration of the GABA reuptake inhibitor tiagabine does not alter the effects of oral cocaine in humans. Drug Alcohol Depend 76:81–91

    Article  PubMed  CAS  Google Scholar 

  144. Lile JA, Stoops WW, Hays LR, Rush CR (2008) The safety, tolerability, and subject-rated effects of acute intranasal cocaine administration during aripiprazole maintenance II: increased aripipirazole dose and maintenance period. Am J Drug Alcohol Abuse 34:721–729

    Article  PubMed  Google Scholar 

  145. Lobmaier P, Kornor H, Kunoe N, Bjornal A (2008) Sustained-release naltrexone for opioid dependence. Cochrane Database Syst Rev, Issue 2. Art. No.: CD006140, doi:10.1002/14651858.CD006140.pub.2

    Google Scholar 

  146. Malcolm R, LaRowe S, Cochran K, Moak D, Herron J, Brady K, Hedden S, Woolson R, Halushka P (2005) A controlled trial of amlodipine for cocaine dependence: a negative report. J Subst Abuse Treatment 28:197–204

    Article  Google Scholar 

  147. Malcolm R, Olive MF, Lechner W (2008) The safety of disulfiram for the treatment of alcohol and cocaine dependence in randomized clinical trials: guidance for clinical practice. Expert Opinion Drug Safety 7:459–472

    Article  CAS  Google Scholar 

  148. Mann K, Lehert P, Morgan MY (2004) The efficacy of acamprosate in the maintenance of abstinence in alcohol-dependent individuals: results of a meta-analysis. Alcohol Clin Exp Res 28:51–63

    Article  PubMed  Google Scholar 

  149. Mansbach RS, Feltner DE, Gold LH, Schnoll SH (2003) Incorporating the assessment of abuse liability into the drug discovery and development process. Drug Alcohol Depend 70:S73–S85

    Article  PubMed  CAS  Google Scholar 

  150. Margolin A, Avants SK, Kosten TR (1995) Mazindol for relapse prevention to cocaine abuse in methadone-maintained patients. Am J Drug Alcohol Abuse 21:469–481

    Article  PubMed  CAS  Google Scholar 

  151. Martin, CS, Earleywine, M, Musty, RE, Perrine MW, Swift, RM (1993) Development and validation of the biphasic alcohol effects scale. Alcohol Clin Exp Res 17:140–146

    Article  PubMed  CAS  Google Scholar 

  152. Martin WR, Jasinski DR, Manskey PA (1973) Naltrexone, an antagonist for the treatment of heroin dependence. Arch Gen Psychiatry 28:784–791

    Article  PubMed  CAS  Google Scholar 

  153. Martin WR, Sloan JW, Sapira JD, Jasinski DR (1971) Physiologic, subjective, and behavioral effects of amphetamine, methamphetamine, ephedrine, phenmetrazine, and methylphenidate in man. Clin Pharmacol Therap 12:245–258

    CAS  Google Scholar 

  154. Mayfield RD, Harris RA, Schuckit MA (2008) Genetic factors influencing alcohol dependence. Br J Pharmacol 154:275–287

    Article  PubMed  CAS  Google Scholar 

  155. McCance-Katz, EF, Kosten TR, Jatlow P (1998) Disulfiram effects on acute cocaine administration. Drug Alcohol Depend 52:27–39

    Article  PubMed  CAS  Google Scholar 

  156. McCaul ME, Wand GS, Stauffer R, Lee, SM, Rohde CA (2001) Naltrexone dampens ethanol-induced cardiovascular and hypothalamic-pituitary-adrenal axis activation. Neuropharmacology 25:537–547

    CAS  Google Scholar 

  157. McKay D, Schare ML (1999) The effects of alcohol and alcohol expectancies on subjective reports and physiological reactivity: a meta-analysis. Addictive Behaviors 24:633–647

    Article  PubMed  CAS  Google Scholar 

  158. McNair DM, Lorr M, Droppleman LF (1971) Manual of the profile of mood states. Educational and Industrial Testing Service, San Diego, CA

    Google Scholar 

  159. Mello NK, Mendelson JH (1980) Buprenorphine suppresses heroin use by heroin addicts. Science 207:657–659

    Article  PubMed  CAS  Google Scholar 

  160. Mello NK, Mendelson JH, Kuehnle JC, Sellers MS (1981) Operant analysis of human heroin self-administration and the effects of naltrexone. J Exp Ther 216:45–54

    CAS  Google Scholar 

  161. Mendelson JH (1991) Protection of participants and experimental design in clinical abuse liability testing. Br J Addict 86:1543–1548

    Article  PubMed  CAS  Google Scholar 

  162. Mendelson J, Jones RT, Welm S, Baggott M, Fernandez I, Melby AK, Nath RP (1999) Buprenorphine and naloxone combinations: The effects of three dose ratios in morphine-stabilized, opiate-dependent volunteers. Psycho-pharmacology 141:37–46

    Article  PubMed  CAS  Google Scholar 

  163. Miranda R Jr, MacKillop J, Monti PM, Rohsenow DJ, Tidey J, Gwaltney C, Swift R, Ray L, McGeary J (2008) Effects of topiramate on urge to drink and the subjective effects of alcohol: a preliminary laboratory study. Alcohol Clin Exp Res 32:489–497

    Article  PubMed  CAS  Google Scholar 

  164. Monti PM, Rohsenow DJ, Hutchison KE, Swift RM, Mueller TI, Colby SM, Brown RA, Gulliver SB, Gordon A, Abrams DB (1999) Naltrexone’s effect on cue-elicited craving among alcoholics in treatment. Alcohol Clin Exp Res 23:1386–1394

    PubMed  CAS  Google Scholar 

  165. Montoya ID, Gorelick DA, Preston KL, Schroeder JR, Umbricht A, Cheskin LJ, Lange WR, Contoreggi C, Johnson RE, Fudala PJ (2004) Randomized trial of buprenorphine for treatment of concurrent opiate and cocaine dependence. Clin Pharm Ther 75:34–48

    Article  CAS  Google Scholar 

  166. Muntaner C, Kumor KM, Nagoshi C, Jaffe JH (1991) Effects of nifedipine pretreatment on subjective and cardiovascular responses to intravenous cocaine in humans. Psychopharmacology 105:37–41

    Article  PubMed  CAS  Google Scholar 

  167. Nann-Vernotica E, Donny EC, Bigelow GE, Walsh SL (2001) Repeated administration of the D1/5 antagonist ecopipam fails to attenuate the subjective effects of cocaine. Psychopharmacology 155:338–347

    Article  PubMed  CAS  Google Scholar 

  168. Nelson RA, Boyd SJ, Ziegelstein RC, Herning R, Cadet JL, Henningfield JE, Schuster CR, Conoreggi C, Gorelick DA (2006) Effect of rate of administration on subjective and physiological effects of intravenous cocaine in humans. Drug Alcohol Depend 82:19–24

    Article  PubMed  CAS  Google Scholar 

  169. Nemeth-Coslett R, Henningfield JE, O’Keeffe MK, Griffiths RR (1986) Effects of mecamylamine on human cigarette smoking and subjective ratings. Psychopharmacology 88:420–425

    Article  PubMed  CAS  Google Scholar 

  170. Nemeth-Coslett R, Henningfield JE, O’Keeffe MK, Griffiths RR (1987) Nicotine gum: dose-related effects on cigarette smoking and subjective effects. Psychopharmacology 92:424–430.

    Article  PubMed  CAS  Google Scholar 

  171. Newton TF, Kalechstein A, Beckson M, Bartzokis G, Bridge TP, Ling W (1999) Effects of selegiline pretreatment on response to experimental cocaine administration. Psychiatry Res 87:101–106

    Article  PubMed  CAS  Google Scholar 

  172. Newton TF, Ling W, Kalechstein AD, Uslaner J, Tervo K (2001) Risperidone pre-treatment reduces the euphoric effects of experimentally-administered cocaine. Psychiatry Res 102:227–233

    Article  PubMed  CAS  Google Scholar 

  173. Newton TF, Roache JD, De Le Garza R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R (2005) Safety of intravenous methamphetamine administration during treatment with bupropion. Psychopharmacology 182(3):426–435

    Article  PubMed  CAS  Google Scholar 

  174. Newton TF, Roache JD, De La Garza R, Fong T, Wallace CL, Li SH, Elkashef A, Chiang N, Kahn R (2006) Buproprion reduces methamphetamine-induced subjective effects and cue-induced craving. Neuropsychopharmacology 7:1537–1544

    Article  CAS  Google Scholar 

  175. Newton TF, Reid MS, De La Garza R, Mahoney JJ, Abad A, Condos R, Palamar J, Halkitis PN, Mojisak J, Anderson A, Li SH, Elkashef A (2008). Evaluation of subjective effects of aripiprazole and methamphetamine in methamphetamine-dependent volunteers. Int J Neuropsychopharmacol 11:1037–1045

    Article  PubMed  CAS  Google Scholar 

  176. O’Brien, CP, Childress AR, McLellan, AT, Ehrman R (1992) Classical conditioning in drug-dependent humans. Ann NY Acad Sci 654:400–415

    Article  PubMed  Google Scholar 

  177. O’Brien, CP, Childress AR, McLellan, AT, Ehrman R, Ternes JW (1988) Types of conditioning found in drug-dependent humans. In: Ray BA (ed) Learning factors in substance abuse. NIDA Res Monogr, 84:44–61

    Google Scholar 

  178. O’Brien CP, Gardner EL (2005) Critical assessment of how to study addiction and its treatment: human and non-human animal models. Pharmacol Therap 108:18–58

    Article  CAS  Google Scholar 

  179. Oliveto A, McCance-Katz FE, Singha A, Petrakis I, Hameedi F, Kosten TR (2001) Effects of cocaine prior to and during bupropion maintenance in cocaine-abusing volunteers. Drug Alcohol Depend 63:155–167

    Article  PubMed  CAS  Google Scholar 

  180. O’Malley SS, Jaffe AJ, Chang G, Schottenfeld RS, Meyer RE, Rounsaville B (1992) Naltrexone and coping skills therapy for alcohol dependence: a controlled study. Arch Gen Psychiatr 49:881–887

    Article  PubMed  Google Scholar 

  181. O’Malley SS, Krishnan-Sarin S, Farren C, Sinha R, Kreek MJ (2002) Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. Psychopharmacology 160:19–29

    Article  PubMed  CAS  Google Scholar 

  182. Ooteman W, Koeter MW, Verheul R, Schippers GM, van den Brink W (2007) The effect of naltrexone and acamprosate on cue-induced craving, autonomic nervous system and neuroendocrine reactions to alcohol-related cues in alcoholics. Eur Neuropsychopharmacol 17:558–66

    Article  PubMed  CAS  Google Scholar 

  183. Patapis NS, Nordstrom BR (2006) Research on naltrexone in the criminal justice system. J Subst Abuse Treat 31:113–115

    Article  PubMed  Google Scholar 

  184. Perkins KA, Fonte C, Meeker, White W, Wilson A (2001) The discriminative stimulus and reinforcing effects of nicotine in humans following nicotine pretreatment. Behav Pharmacol 12:35–44

    Article  PubMed  CAS  Google Scholar 

  185. Perkins KA, Grobe J, Fonte C (1997) Influence of acute smoking exposure on the subsequent reinforcing value of smoking. Exp Clin Psychopharmacol 5:277–285

    Article  PubMed  CAS  Google Scholar 

  186. Pickens RW, Johanson CE (1992) Craving: consensus of status and agenda for future research. Drug Alcohol Depend 30:127–131

    Article  PubMed  CAS  Google Scholar 

  187. Preston KL, Bigelow GE (1991) Subjective and discriminative effects of drugs. Behav Pharmacol 2:293–313

    Article  PubMed  Google Scholar 

  188. Preston KL, Jasinski DR (1991) Abuse liability studies of opioid agonist-antagonists in humans. Drug Alcohol Depend 28:49–82

    Article  PubMed  CAS  Google Scholar 

  189. Preston KL, Sullivan JT, Berger P, Bigelow GE (1993) Effects of cocaine alone and in combination with mazindol in human cocaine abusers. J Pharmacol Exp Ther 267:296–307

    PubMed  CAS  Google Scholar 

  190. Preston KL, Sullivan JT, Strain EC, Bigelow GE (1992) Effects of cocaine alone and in combination with bromocriptine in human cocaine abusers. J Pharmacol Exp Ther 262:279–291

    PubMed  CAS  Google Scholar 

  191. Preston KL, Walsh SL, Sannerud CA (1997) Measures of interoceptive stimulus effects: relationship to drug reinforcement. In: Johnson BA, Roache JD (eds) Drug addiction and its treatment: nexus of neuroscience and behavior. Lippincott-Raven, Philadelphia, pp 91–114

    Google Scholar 

  192. Raby K (1953) Investigations on the disulfiram-alcohol reaction. Q J Stud Alcohol 14:545–556

    PubMed  CAS  Google Scholar 

  193. Roache JD (1991) Performance and physiological measures in abuse liability evaluation. Br J Addict 86:1595–1600

    Article  PubMed  CAS  Google Scholar 

  194. Roache JD (1999) Human laboratory safety evaluations in cocaine-dependent patients. In: Harris LS (ed) Problems of drug dependence 1998: proceedings of the 60th annual meeting of the college on problems of drug dependence, National institute on drug abuse research monograph, vol 179. U.S. Government Printing Office, Washington, DC, p 38

    Google Scholar 

  195. Roache JD, Creson DL, La Vergne C, Grabowski J (1998) Human laboratory evaluation of cocaine and d-Amphetamine drug interactions. Presented at the Annual Scientific Meeting of the Texas Research Society on Alcoholism (TRSA), San Antonio, TX

    Google Scholar 

  196. Roache JD, Grabowski J, Schmitz JM, Creson DL, Rhoades HM (2000) Laboratory measures of methylphenidate effects in cocaine-dependent patients receiving treatment. J Clin Psychopharmacol 20:61–68

    Article  PubMed  CAS  Google Scholar 

  197. Roache JD, Griffiths RR (1989) Diazepam and triazolam self-administration in sedative abusers: concordance of subject ratings, performance, and drug self-administration. Psychopharmacology 99:309–315

    Article  PubMed  CAS  Google Scholar 

  198. Roache JD, Griffiths RR (1989) Abuse liability of anxiolytics and sedative/hypnotics: methods assessing the likelihood of abuse. In: Fischman MW, Mello NK (eds)Testing for abuse liability of drugs in humans. NIDA research Monograph, vol 92. DHEW Pub. No. (ADM) 89–163, U.S. Government Printing Office, Washington, DC, pp 123–146

    Google Scholar 

  199. Roache JD, Johnson BA, Ait-Daoud N, Mauldin JB, Thornton JE, Wells LT, Murff WL (2005) Effects of repeated-dose isradipine on the abuse liability of cocaine. Exp Clin Psychopharmacol 13:319–326

    Article  PubMed  CAS  Google Scholar 

  200. Roache JD, Kuhar MJ, Glowa JR, Grabowski J, Levin F, Walsh SL (1999) Agonist-type approaches to the treatment of cocaine dependence. In: Harris LS (ed) Problems of drug dependence 1998: proceedings of the 60th annual meeting of the college on problems of drug dependence. NIDA research monograph, vol 179. U.S. Government Printing Office, Washington, DC, pp 37–39

    Google Scholar 

  201. Roache JD, Meisch RA (1991) Drug self-administration research in drug and alcohol addiction. In: Miller NS (ed) Comprehensive handbook of drug and alcohol addiction. Marcel Dekker, New York, pp 625–638

    Google Scholar 

  202. Robbins SJ, Ehrman RN, Childress AR, O’Brien CP (1997) Relationships among physiological and self-report responses produced by cocaine-related cues. Addict Behav 22:157–167

    Article  PubMed  CAS  Google Scholar 

  203. Robbins SJ, Ehrman RN, Childress AR, O’Brien CP (1999) Comparing levels of cocaine cue reactivity in male and female outpatients. Drug Alcohol Depend 53:223–230

    Article  PubMed  CAS  Google Scholar 

  204. Rohsenow DJ, Monti PM, Hutchison KE (2000) Naltrexone’s effects on reactivity to alcohol cues among alcoholic men. J Abnorm Psychol 109:738–742

    Article  PubMed  CAS  Google Scholar 

  205. Rohsenow DJ, Monti PM, Rubonis AV, Sirota AD, Niaura RS, Colby SM, Wunschel SM, Abrams DB (1994) Cue reactivity as a predictor of drinking among male alcoholics. J Consult Clin Psychol 62:620–626

    Article  PubMed  CAS  Google Scholar 

  206. Romach MK, Glue P, Kampman K, Kaplan HL, Soer GR, Poole S, Clarke L, Coffin V, Cornish J, O’Brien CP, Sellers EEM (1999) Attenuation of the euphoric effects of cocaine by the dopamine D1/D5 antagonist Ecopipam (SCH39166). Arch Gen Psychiatry 56:1101–1106

    Article  PubMed  CAS  Google Scholar 

  207. Rose JE, Behm RM, Westman EC, Bates JE (2003) Mecamylamine acutely increases human intravenous nicotine self-administration. Pharmacol Biochem Behav 76:307–313

    Article  PubMed  CAS  Google Scholar 

  208. Sauter AM, Boss D, von Wartburg JP (1977) Reevaluation of the disulfiram-alcohol reaction in man. J Stud Alcohol 38:1680–1695

    PubMed  CAS  Google Scholar 

  209. Schoedel KA, Sellers EM (2008) Assessing abuse liability during drug development: changing standards and expectations. Development 83:622–626

    CAS  Google Scholar 

  210. Schulze D, Jones BT (1999) The effects of alcohol cues and an alcohol priming dose on a multifactorial measure of subjective cue reactivity in social drinkers. Psychopharmacology 145:452–454

    Article  PubMed  CAS  Google Scholar 

  211. Sherer MA, Kumor KM, Jaffee JH (1989) Effects of intravenous cocaine are partially attenuated by haloperidol. Psychiat Res 27:117–125

    Article  CAS  Google Scholar 

  212. Shuckit MA (1994) Low level of response to alcohol as a predictor of future alcoholism. Am J Psychiatr 151:184–189

    Google Scholar 

  213. Silverman K, Kirby KC, Griffiths RR (1994) Modulation of drug reinforcement by behavioral requirements following drug ingestion. Psychopharmacology 114:243–247

    Article  PubMed  CAS  Google Scholar 

  214. Silverstone PH, Johnson B, Cowen PJ (1992) Does ondansetron attenuate amphetamine-induced behavior in human volunteers? Psychopharmacology 107:140–141

    Article  PubMed  CAS  Google Scholar 

  215. Sinha, R, Fuse, T, Aubin, LR, O’Malley, SS (2000) Psychological stress, drug-related cues and cocaine craving. Psychopharmacology 152:140–148

    Article  PubMed  CAS  Google Scholar 

  216. Sinha, R, Talih M, Malison, R, Cooney,N, Anderson, GM, Kreek, MJ (2003) Hypothalamic-pituitary-adrenal axis and sympatho-adreno-medullary responses during stress-induced and drug cue-induced cocaine craving states. Psychopharmacology 170:62–72

    Article  PubMed  CAS  Google Scholar 

  217. Sobel B-FX, Sigmon SC, Griffiths RR (2004) Transdermal nicotine maintenance attenuates the subjective and reinforcing effects of intravenous nicotine, abut not cocaine or caffeine, in cigarette-smoking stimulant abusers. Neuropsychopharmacology 29:991–1003

    Article  PubMed  CAS  Google Scholar 

  218. Sofuoglu M, Kosten TR (2005) Novel approaches to the treatment of cocaine addiction. CNS Drugs 19:13–25

    Article  PubMed  CAS  Google Scholar 

  219. Spiga R, Roache JD (1997) Human drug self-administration: A review and methodological critique. In: Johnson BA, Roache JD (eds) Drug addiction and its treatment: nexus of neuroscience and behavior. Lippincott-Raven, Philadelphia, pp 39–71

    Google Scholar 

  220. Stoops WW (2006) Aripiprazole as a potential pharmacotherapy for stimulant dependence: human laboratory studies with d-amphetamine. Exp Clin Psychopharmacol 14:413–421

    Article  PubMed  CAS  Google Scholar 

  221. Stoops WW, Lile JA, Fillmore MT, Glaser PE, Rush CR (2005) Reinforcing effects of methylphenidate: Influence of dose and behavioral demands following drug administration. Psychopharmacology 177:349–355

    Article  PubMed  CAS  Google Scholar 

  222. Stoops WW, Lile JA, Glaser PE, Rush CR (2005) Discriminative stimulus and self-reported effects of methylphenidate, d-amphetamine, and triazolam in methylphenidate-trained humans. Exp Clin Psychopharmacol 13:56–64

    Article  PubMed  CAS  Google Scholar 

  223. Strain EC, Bigelow GE, Liebson IA, Stitzer ML (1999) Moderate vs. high-dose methadone in the treatment of opioid dependence: a randomized trial. J Am Med Assoc 281:1000–1005

    Article  CAS  Google Scholar 

  224. Sullivan MA, Vosburg SK, Comer SD (2006) Depot naltrexone: Antagonism of the reinforcing, subjective, and physiological effects of heroin. Psychopharmacology 189: 37–46

    Article  PubMed  CAS  Google Scholar 

  225. Swift RM, Davidson D, Whelihan W, Kuznetsov O. (1996) Ondansetron alters human alcohol intoxication. Biol Psychiatry 40:514–521

    Article  PubMed  CAS  Google Scholar 

  226. Swift RM, Whelihan W, Kuznetsov O, Buongiorno G, Hsuing H (1994) Naltrexone-induced alterations in human ethanol intoxication. Am J Psychiatr 151:1463–1467

    PubMed  CAS  Google Scholar 

  227. Tcheremissine OV (2008) Is quetiapine a drug of abuse? Reexamining the issue of addiction. Expert Opinion Drug Safety 7:739–748

    Article  CAS  Google Scholar 

  228. Tiffany ST (1990) A cognitive model of drug urges and drug-use behavior: role of automatic and non-automatic processes. Psychol Rev 97:147–168

    Article  PubMed  CAS  Google Scholar 

  229. Tiffany ST and Conklin CA (2000) Human models in craving research: A cognitive processing model of alcohol craving and compulsive alcohol use. Addiction 95(Suppl):S145–S153

    PubMed  Google Scholar 

  230. Tiffany ST, Sanderson-Cox L, Elsah CA (2000) Effects of trandermal nicotine patches on abstinence-induced and cue-elicited craving in cigarette smokers. J Consulting Clin Psychol 68:233–240

    Article  CAS  Google Scholar 

  231. Tiihonen J, Kuoppasalmi K, Fohr J, Tuomola P, Kuikanmaki O, Vorma H et al (2007). A comparison of aripiprazole, methylphenidate, and placebo for amphetamine dependence. Am J Psychiat 164:160–162

    Article  PubMed  Google Scholar 

  232. Tonstad S (2007) Varenicline for smoking cessation. Expert Rev Neurotherapeutics 7:121–127

    Article  CAS  Google Scholar 

  233. Vocci FJ, Acri J, Elkashef A (2005) Medication development for addictive disorders: the state of the science. Am J Psychiatr 162:1432–1440

    Article  PubMed  Google Scholar 

  234. Vocci FJ, Ling W (2005) Medications development: Successes and challenges. Pharmacol Ther 108:94–108

    Article  PubMed  CAS  Google Scholar 

  235. Volpicelli JR, Alterman AI, Hayashida M, O’Brien CP (1992) Naltrexone in the treatment of alcohol dependence. Arch Gen Psychiatr 49:876–880

    Article  PubMed  CAS  Google Scholar 

  236. Von Wartburg JP, Buhler R (1984) Biology of disease: alcoholism and aldehydism: new disease concepts. Lab Invest 50:5–15

    Google Scholar 

  237. Wachtel SR, Ortengren A, de Wit H (2002) The effects of acute haloperidol or risperidone on subjective responses to methamphetamine in healthy volunteers. Drug Alcohol Depend 68:23–33

    Article  PubMed  CAS  Google Scholar 

  238. Wall TL, Peterson CM, Peterson KP, Johnson ML, Thomasson HR, Cole M, Ehlers CL (1997) Alcohol metabolism in Asian–American men with genetic polymorphisms of aldehyde dehyrdrogenase. Ann Intern Med 127:376–379

    PubMed  CAS  Google Scholar 

  239. Wallace CL, Roache JD, Newton TF, Elkashef A, Kahn R, Mojsiak J, De La Garza R, Chang N (2005) A phase I clinical safety study of the 3-way drug interactions between disulfiram, cocaine, and alcohol in cocaine dependent research volunteers. Presented at the 67th Annual Scientific Meeting of the College on Problems of Drug Dependence (CPDD), Orlando, FL

    Google Scholar 

  240. Walsh SL, Eissenberg T (2003) The clinical pharmacology of buprenorphine: extrapolating from the laboratory to the clinic. Drug Alcohol Depend 70:S13–S27

    Article  PubMed  CAS  Google Scholar 

  241. Walsh SL, Haberny KA, Bigelow BE (2000) Modulation of intravenous cocaine effects by chronic oral cocaine in humans. Psychopharmacology 150:361–373

    Article  PubMed  CAS  Google Scholar 

  242. Walsh SL, Preston KL, Sullivan JT, Fromme R, Bigelow GE (1994) Fluoxetine alters the effects of intravenous cocaine in humans. J Clin Psychopharmacol 14:396–407

    PubMed  CAS  Google Scholar 

  243. Wand GS, McCaul M, Yang X, Reynolds J, Gotjen D, Lee S, Ali A (2001) The mu-opioid receptor gene polymorphism (A118G) alter HPS axis activation induced by opioid receptor blockade. Neuropharmacology 26:106–114

    Google Scholar 

  244. Ward AS, Haney M, Fischman MW, Foltin RW (1997) Binge cocaine self-administration in humans: intravenous cocaine. Psychopharmacology 132:375–381

    Article  PubMed  CAS  Google Scholar 

  245. Weinberger AH, Sacco KA, Creeden CL, Vessicchio JC, Jatlow PI, George TP (2007) Effects of acute abstinence, reinstatement, and mecamylamine on biochemical and behavioral measures of cigarette smoking in schizophrenia. Schizophr Res 91:217–225

    Article  PubMed  Google Scholar 

  246. White PF (1988) Use of patient-controlled analgesia for management of acute pain. J Am Med Assoc 259:243–247

    Article  CAS  Google Scholar 

  247. White TL, Lott DC, de Wit H (2006) Personality and the subjective effects of acute amphetamine in healthy volunteers. Neuropsychopharmacology 31:1064–1074

    Article  PubMed  CAS  Google Scholar 

  248. Wikler A (1952) A psychodynamic study of a patient during experimental self-regulated re-addiction to morphine. Psychiatric Q 26:270–293

    Article  CAS  Google Scholar 

  249. Wikler A (1968) Interaction of physical dependence and classical and operant conditioning in the genesis of relapse. In: Association for Research in Nervous and Mental Disease (ed) The addictive states: proceedings of the association, New York, NY, 2–3 December 1966. Williams & Wilkins, Baltimore, pp 280–286

    Google Scholar 

  250. Wikler A (1973) Dynamics of drug dependence: Implications of a conditioning theory for research and treatment. Arch Gen Psychiat 28:611–616

    Article  PubMed  CAS  Google Scholar 

Download references

Author information

Authors and Affiliations

  1. Department of Psychiatry, The University of Texas Health Science Center at San Antonio, San Antonio, TX, USA

    John D. Roache

Authors
  1. John D. Roache
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to John D. Roache .

Editor information

Editors and Affiliations

  1. , Depts Psychiat & Neurobehav Sciences, Me, University of Virginia, Charlottesville, 22908, Virginia, USA

    Bankole A. Johnson

Rights and permissions

Reprints and permissions

Copyright information

© 2010 Springer Science+Business Media, LLC

About this chapter

Cite this chapter

Roache, J.D. (2010). Role of the Human Laboratory in the Development of Medications for Alcohol and Drug Dependence. In: Johnson, B. (eds) Addiction Medicine. Springer, New York, NY. https://doi.org/10.1007/978-1-4419-0338-9_7

Download citation

  • DOI: https://doi.org/10.1007/978-1-4419-0338-9_7

  • Published:

  • Publisher Name: Springer, New York, NY

  • Print ISBN: 978-1-4419-0337-2

  • Online ISBN: 978-1-4419-0338-9

  • eBook Packages: MedicineMedicine (R0)

Publish with us

Policies and ethics

Search

Navigation